<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111422</url>
  </required_header>
  <id_info>
    <org_study_id>Ewha 219-3-40</org_study_id>
    <nct_id>NCT01111422</nct_id>
  </id_info>
  <brief_title>Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients</brief_title>
  <official_title>A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal
      dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage
      during PD still remain unclear, generation of reactive oxygen species may be responsible for
      progressive membrane dysfunction. N-acetylcysteine (NAC)is a powerful antioxidant shown to
      protect peritoneal fibrosis in peritoneal dialysis animal model. In this study the
      researchers investigated the hypothesis that NAC protect peritoneal membrane damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-Acetylcysteine (NAC) is known to be relatively safe and beneficial in peritoneal dialysis
      patient at a dose of 1200 mg per day. Patients will be randomly assigned to NAC and control
      group and prescribed according to the protocol. At 2 and 6 month, Peritoneal equilibrium test
      (PET) will be performed with blood sampling.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal membrane function</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in peritoneal membrane function (Δ D/Pcreatinine, ΔD/Purea) with peritoneal equilibrium test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxydative stress status</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of oxydative stress status with plasma and RBC (GSH/GSSG, 8-OHdG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mesothelial cell transformation (Epithelial to Mesenchymal Transition)</measure>
    <time_frame>6 month</time_frame>
    <description>Morphology was analysed with peritoneal dialysate isolated mesothelial cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual renal function</measure>
    <time_frame>6 month</time_frame>
    <description>Changes in residual renal function (ΔKt/Vurea, ΔeGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal membrane function</measure>
    <time_frame>2 months</time_frame>
    <description>Changes in peritoneal membrane function (Δ D/Pcreatinine, ΔD/Purea) with peritoneal equilibrium test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>End-Stage Kidney Disease</condition>
  <condition>Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Age and sex matched peritoneal dialysis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine in stable peritoneal dialysis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>Muteran capsuleⓇ HAN WHA PHARM.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maintenance peritoneal dialysis at least 3 months

          -  Patients who are able and willing to understand, sign and date an informed consent
             document, and authorize access to protected health information

        Exclusion Criteria:

          -  Episode of peritonitis at least 3 months

          -  Episodes of admission due to other disease at lease 3 months

          -  Liver disease

          -  Allergic history with N-acetylcysteine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hee Kang, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mina Yu, MD</last_name>
    <phone>+82-2-2650-2562</phone>
    <email>yuelizabeth@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun-Jung Kim, NR</last_name>
    <phone>+82-2-2650-5497</phone>
    <email>40739@eumc.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Yu, MD</last_name>
      <phone>+82-2-2650-2562</phone>
      <email>yuelizabeth@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Jung Kim, Nurse</last_name>
      <phone>+82-2-2650-5497</phone>
    </contact_backup>
    <investigator>
      <last_name>Duk-Hee Kang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://celltranslab.new21.net/</url>
    <description>Cell Transformation Control Laboratory</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>April 26, 2010</last_update_submitted>
  <last_update_submitted_qc>April 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nephrology</name_title>
    <organization>Ewha Womans University Mokdong Hospital</organization>
  </responsible_party>
  <keyword>Antioxidant</keyword>
  <keyword>Epithelial to Mesenchymal Transition</keyword>
  <keyword>peritoneal fibrosis</keyword>
  <keyword>Peritoneal Dialysis, Continuous Ambulatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

